Gilead Sciences Inc (BUE:GILD)
ARS 26600 125 (0.47%) Market Cap: 111.51 Tn Enterprise Value: 131.94 Tn PE Ratio: 110.08 PB Ratio: 6.15 GF Score: 52/100

Q4 2019 Gilead Sciences Inc Earnings Call Transcript

Feb 04, 2020 / 09:30PM GMT
Operator

Ladies and gentlemen, thank you for standing by, and welcome to the Gilead Sciences Fourth Quarter 2019 Earnings Conference Call. My name is Liz, and I will be your operator today. (Operator Instructions) And as a reminder, this conference call is being recorded.

I would now like to turn the call over to Douglas Maffei from Investor Relations. Please go ahead.

Douglas Maffei;Senior Director
Investor Relations,

Thank you, Liz, and good afternoon, everyone. Just after market close today, we issued a press release with earnings results for fourth quarter and full year 2019. The press release and detailed slides are available on the Investor Relations website.

Speakers on today's call will be Daniel O'Day, Chairman and Chief Executive Officer; Andrew Dickinson, Chief Financial Officer; Johanna Mercier, Chief Commercial Officer; and Merdad Parsey, Chief Medical Officer. Also in the room are Christi Shaw, Chief Executive Officer of Kite; and Diana Brainard, Senior Vice President and Head of our HIV and Emerging Virus Therapeutic

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot